US EditionPublished • loading... • Updated
Adverse Event Profiles Associated with CDK4/6 Inhibitors | Pharmacy Times - Pharmacy Practice News and Expert Insights
Summary by Pharmacy Times
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Adverse Event Profiles Associated with CDK4/6 Inhibitors | Pharmacy Times - Pharmacy Practice News and Expert Insights
Panelists discuss how treatment selection between CDK4/6 inhibitors in early-stage breast cancer is primarily driven by trial eligibility criteria with abemaciclib being preferred when qualified, while in metastatic settings ribociclib is often favored due to overall survival data, and how adverse event profiles differ significantly among the 3 agents (neutropenia with palbociclib/ribociclib, QTc prolongation and drug interactions with ribocicli…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
